lansoprazole has been researched along with Duodenal Ulcer in 150 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Duodenal Ulcer: A PEPTIC ULCER located in the DUODENUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clinical experience with lansoprazole in the acute treatment of duodenal ulcer patients has been compared with treatment using placebo, H2-antagonists or omeprazole." | 10.17 | Acute treatment of duodenal ulcer: experience with lansoprazole. ( Mignon, M; Vallot, T, 1993) |
| " This study aimed to establish the noninferiority of keverprazan to lansoprazole in the treatment of patients with duodenal ulcer (DU)." | 9.69 | Efficacy and Safety of Keverprazan Compared With Lansoprazole in the Treatment of Duodenal Ulcer: A Phase III, Randomized, Double-Blind, Multicenter Trial. ( Chen, HH; Chen, HX; Chen, MH; Guo, QH; Li, FF; Li, SB; Li, X; Liao, AJ; Liu, CX; Liu, XW; Liu, YL; Miao, XP; Tan, ND; Tang, YP; Wu, H; Xia, M; Xiao, YL; Zhang, Y; Zhang, ZY, 2023) |
| "In this phase 3, randomized (1:1), double-blind, double-dummy, parallel-group, non-inferiority study (April 5, 2017, to July 19, 2019), patients with ≥ 1 endoscopically confirmed duodenal ulcer, at 52 hospitals (China, South Korea, and Taiwan), received vonoprazan 20 mg once daily (QD) or lansoprazole 30 mg QD for 6 weeks maximum." | 9.51 | Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients. ( Chiu, CT; Chong, CF; Chung, WC; Gu, L; Hou, X; Kudou, K; Meng, F; Sha, W; Wang, J; Zhang, S, 2022) |
| " lansoprazole, a proton pump inhibitor, for treatment of gastric ulcer (GU) or duodenal ulcer (DU)." | 9.24 | Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials. ( Miwa, H; Mori, Y; Nishimura, A; Sakaki, N; Sakurai, Y; Takanami, Y; Tatsumi, T; Uedo, N; Watari, J, 2017) |
| "Low-dose lansoprazole has not been intensively evaluated for its efficacy in the prevention of recurrent gastric or duodenal ulcers in patients receiving long-term non-steroidal anti-inflammatory drug (NSAID) therapy for pain relief in such diseases as rheumatoid arthritis, osteoarthritis, and low back pain." | 9.16 | Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. ( Asaka, M; Ashida, K; Hiraishi, H; Hiramatsu, N; Kanto, T; Katsuo, S; Kontani, T; Matsui, S; Mizokami, Y; Sakaki, N; Soen, S; Sugano, K; Takei, Y; Takeuchi, T, 2012) |
| "The efficacy of low-dose lansoprazole has not been established for the prevention of recurrent gastric or duodenal ulcers in those receiving long-term low-dose aspirin (LDA) for cardiovascular and cerebrovascular protection." | 9.15 | Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. ( Abe, S; Ashida, K; Chiba, T; Hiramatsu, N; Itabashi, T; Kanto, T; Matsui, S; Matsumoto, Y; Mizokami, Y; Sakaki, N; Shimada, K; Sugano, K; Uchiyama, S; Uemura, N, 2011) |
| "Sixty-seven patients (49 with Zollinger-Ellison syndrome [ZES], 18 without), with basal acid output (BAO) >15 mmol/h or >5 mmol/h if post-antrectomy (n = 9, all ZES), were treated with individually optimized doses of lansoprazole (7." | 9.11 | Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. ( Hirschowitz, BI; Mohnen, J; Simmons, J, 2005) |
| "To compare lansoprazole 30 mg once daily, lansoprazole 15 mg once daily and ranitidine 150 mg once nightly in the prevention of duodenal ulcer relapse in patients whose duodenal ulcers had been previously healed with lansoprazole 30 mg once daily or ranitidine 300 mg nightly." | 9.09 | Lansoprazole is superior to ranitidine as maintenance treatment for the prevention of duodenal ulcer relapse. ( Bardhan, KD; Crouch, SL; Crowe, J; Keeling, PN; Thompson, RP; Trewby, PN; Weir, D, 1999) |
| "Lansoprazole safely and effectively reduces duodenal ulcer recurrence and ulcer-related symptoms." | 9.09 | Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2-receptor antagonists. ( Campbell, D; Haber, M; Jennings, DE; Kovacs, TO; Richter, J; Rose, P, 1999) |
| "The aim of this randomized, multicenter, double-masked, parallel-group study was to compare the efficacy of lansoprazole with that of omeprazole monotherapy in duodenal ulcer healing and prevention of relapse." | 9.09 | Lansoprazole versus omeprazole for duodenal ulcer healing and prevention of relapse: a randomized, multicenter, double-masked trial. ( Dobrilla, G; Fiocca, R; Piazzi, L, 1999) |
| "To compare two lansoprazole-based non-clarithromycin triple therapies and one dual therapy in a prospective double-blind placebo-controlled study of Helicobacter pylori eradication and duodenal ulcer healing." | 9.09 | Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. ( Carpio, RE; Fock, KM; Ho, J; Hu, FL; Hu, PJ; Huang, NX; Kachintorn, U; Kullavanijaya, P; Lam, SK; Lesmana, L; Li, YY; Manan, C; Perez, JY; Phornphutkul, K; Qian, SC; Wong, BC; Xiao, SD, 2000) |
| "The primary objective of the present study was to evaluate the efficacy of 30 and 60 mg of lansoprazole administered in combination with two antibiotics for 7 or 10 days in eradicating Helicobacter pylori in duodenal ulcer patients." | 9.09 | [Treatment of Helicobacter pylori infection with lansoprazole 30 mg or 60 mg combined with two antibiotics for duodenal ulcers]. ( Joubert-Collin, M; Lamouliatte, H; Perie, F, 2000) |
| "The aim of this study was to compare in an open, controlled and prospective trial the efficacy of one-week regimen using either lansoprazole (2 x 30 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group I, 60 cases) or ranitidine bismuth citrate (2 x 400 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group II, 61 cases) on the eradication of Hp infection in duodenal ulcer patients." | 9.09 | [Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer]. ( Buzás György, M; Illyés, G; Székely, E; Széles, I, 2000) |
| " Fifty patients with active or scarred duodenal ulcer were randomized to lansoprazole or omeprazole for 1 to 4 weeks, with clarithromycin 250 mg twice a day and tinidazole 500 mg twice a day for the first week." | 9.09 | Long-term follow-up and serologic assessment after triple therapy with omeprazole or lansoprazole of Helicobacter-associated duodenal ulcer. ( Fanti, L; Guslandi, M; Ieri, R; Mezzi, G; Passaretti, S; Testoni, PA, 2001) |
| " pylori-positive duodenal ulcers were randomized to receive either lansoprazole 30 mg, clarithromycin 500 mg, and metronidazole 400 mg twice daily for 7 days (LCM-7) or lansoprazole 30 mg, clarithromycin 500 mg, metronidazole 400 mg, and bismuth subcitrate 240 mg twice daily for 3 days (LCMB-3)." | 9.09 | Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study. ( Chan, CK; Chu, KM; Fung, FM; Hu, FL; Hu, WH; Hui, WM; Kung, NN; Lai, KC; Lam, SK; Lau, GK; Liu, XG; Wang, WH; Wong, BC; Wong, WM; Yuen, MF, 2001) |
| "This study was undertaken to compare the efficacy of lansoprazole (LAN)-based triple therapy with that of RBC-based dual therapy in H pylori-infected patients with duodenal ulcer." | 9.09 | Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study. ( Belmonte, A; Cavaliere, C; Ciliberto, E; Fiocca, R; Frandina, C; Giglio, A; Luzza, F; Pallone, F; Saccà, N; Trimboli, V, 2001) |
| " pylori positive duodenal ulcer were enrolled and randomly allocated into one of the five treatment groups: 1) group A: received lansoprazole 30 mg once daily for 2 weeks plus amoxicillin (AM) 500 mg and metronidazole (MZ) 500 mg twice daily for one week in the first week; 2) group B: the AM in group A was replaced by clarithromycin (CM) 250 mg; 3) group C: the MZ in group A was replaced by CM 250 mg; 4) group D: the AM and CM in group C was used for 2 wk; 5) group E: the CM in group D was doubled to 500 mg twice daily." | 9.09 | A multicenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy. ( Hsu, CT; Kuo, CF; Wang, CS; Wang, TH; Yang, JC; Yang, KC, 1999) |
| "Satisfactory antral biopsies were obtained from 119 duodenal ulcer patients before and after 4 wk of therapy with lansoprazole, ranitidine, or placebo." | 9.08 | The effects of short-term lansoprazole therapy on Helicobacter pylori infection and antral gastritis in duodenal ulcer patients. ( Atkinson, BF; Brightman, SA; Jhala, NC; McFarland, MM; Morale, B; Rubin, W, 1995) |
| "This study reports preliminary results of a controlled, multicenter trial on the quality of ulcer healing induced by lansoprazole (LPZ) or roxatidine (R) in gastric ulcer (GU) or duodenal ulcer (DU) patients." | 9.08 | Quality of peptic ulcer healing induced by lansoprazole and roxatidine. ( Fujino, MA; Kobayashi, K; Morozumi, A; Ohtsuka, H; Sano, S; Suzuki, Y; Tachikawa, H; Uchida, N; Ueda, F; Yamamoto, Y, 1995) |
| "The clinical usefulness of lansoprazole in the healing of gastric and duodenal ulcers, the S2-stage shift rate (white scarring rate), and endoscopic healing rate with respect to degree of gastric mucosal atrophy were investigated." | 9.08 | Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group. ( Asaki, S; Hongo, M; Sakurada, H; Sato, A; Takeda, T; Toyota, T, 1995) |
| "In the present study, the effects of short-term treatment with lansoprazole on healing and recurrence of peptic ulcer were investigated." | 9.08 | The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody. ( Akimoto, K; Fukujin, H; Katoaka, A; Mashima, H; Mine, T; Nagasawa, J; Tajima, A; Takano, T; Tsuchida, T; Yasuda, H, 1995) |
| "In this double-blind randomized comparative study patients with active duodenal ulcers were treated with either 30 mg lansoprazole or 20 mg omeprazole in the morning." | 9.08 | Lansoprazole versus omeprazole in active duodenal ulcer. A double-blind, randomized, comparative study. ( Anker-Hansen, O; Carling, L; Ekström, P; Sellström, H; Sjöstedt, S; Unge, P, 1995) |
| "A double-blind, multicentre study was undertaken in 296 patients with endoscopically proven duodenal ulcer to compare the efficacy and safety of lansoprazole 15, 30 or 60 mg with placebo." | 9.08 | A comparison of three doses of lansoprazole (15, 30 and 60 mg) and placebo in the treatment of duodenal ulcer. The Lansoprazole Study Group. ( Avner, DL; Dorsch, ER; Greski-Rose, PA; Jennings, DE, 1995) |
| "To evaluate the efficacy of a second generation acid pump inhibitor-lansoprazole (L) a controlled clinical trial in 72 patients of duodenal ulcer was carried out with omeprazole (O) as control." | 9.08 | [A clinical trial of lansoprazole in the treatment of duodenal ulcer]. ( Chen, S; Pei, Y; Wang, B, 1995) |
| " pylori-positive duodenal ulcer were randomly assigned to receive one of the following three antiulcer regimens: (1) lansoprazole 30 mg b." | 9.08 | Comparison of two lansoprazole-antibiotic combinations (amoxycillin or classical triple therapy) for treatment of H. pylori infection in duodenal ulcer patients. ( Bargiggia, S; Bianchi Porro, G; Colombo, E; Maconi, G; Parente, F, 1996) |
| "We report long-term, up to 4 years, prospective treatment using lansoprazole in nine male patients with duodenal ulcers and a BAO of more than 15 mmol/h whose results are compared with those in 10 male Zollinger-Ellison syndrome patients with intact stomachs reported in detail in an accompanying paper." | 9.08 | Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h. ( Hirschowitz, BI; Mohnen, J; Shaw, S, 1996) |
| "Eighty patients with endoscopically proven active duodenal ulcer were randomized to take ranitidine or lansoprazole for 4-8 wk, together with clarithromycin 250 mg b." | 9.08 | Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer. ( Bargiggia, S; Bianchi Porro, G; Lazzaroni, M, 1997) |
| " The aim of the present study was to assess efficacy and tolerability of the proton pump inhibitors lansoprazole given at bedtime as compared to ranitidine, both in acute and maintenance treatment of duodenal ulcer." | 9.08 | Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial. ( Dattilo, M; Russo, A, 1997) |
| " Fasting had no influence on the result of duodenal ulcer treatment by lansoprazole which was well tolerated." | 9.08 | [Effect of the observance of diurnal fast of Ramadan on duodenal ulcer healing with lansoprazole. Results of a prospective controlled study]. ( Ajmi, S; Mehdi, A, 1997) |
| " pylori-infected duodenal ulcer patients we investigated the gastritis parameters in antral and corpus mucosa before treatment, after 6 and 12 months of therapy, and 6 months after termination of treatment with 15 mg lansoprazole or 150 mg ranitidine/day." | 9.08 | Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. ( Kiel, G; Meining, A; Stolte, M, 1998) |
| "To study in a double-blind controlled manner the effects of lansoprazole 15 mg or 30 mg daily compared with ranitidine 300 mg once daily and placebo in the relieving of symptoms and healing of acute duodenal ulceration." | 9.07 | Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Lansoprazole Study Group. ( Goff, J; Greski-Rose, P; Jennings, D; Lanza, F; Scowcroft, C, 1994) |
| "The purpose of this study was to compare duodenal ulcer healing, symptom relief, and safety of lansoprazole (a new proton pump inhibitor) given at doses of 30 mg and 60 mg, in the morning with ranitidine 300 mg at bedtime." | 9.07 | Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine. ( Bardhan, KD; Christian, J; Cochran, KM; Hawkey, CJ; Long, RG; Moules, IK; Wormsley, KG, 1993) |
| "The efficacy of lansoprazole (30 mg/d) and omeprazole (20 mg/d) has been assessed in active duodenal ulcer disease in 144 patients included in a multicentric, randomized, double-blind trial." | 9.07 | [Comparison of lansoprazole (30 mg) and omeprazole (20 mg) in the treatment of duodenal ulcer. A multicenter double-blind comparative trial]. ( Andrieu, J; Coste, T; Dupuis, J; Grimaud, JC; Julien, H; Lemerez, M; Licht, H; Petite, JP; Sallerin, V; Slama, JL, 1993) |
| "Forty-two patients with peptic ulceration of the duodenum, stomach or oesophagus, who had not responded to 3 or more months of high-dose treatment with ranitidine (450 or 600 mg/day), were treated with oral lansoprazole at 30-60 mg daily." | 9.07 | An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. ( Arnold, R; Brunner, G; Fuchs, W; Hennig, U, 1993) |
| " In this 2:1 randomized, double-blind, multicentre trial lansoprazole 30 mg am was compared to 40 mg famotidine nocte in 264 out-patients suffering from uncomplicated duodenal ulcer." | 9.07 | Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration. ( Grymbowski, T; Hennig, U; Hotz, J; Kleinert, R; Schwarz, JA, 1992) |
| " This randomized, double-blind multicentre trial studied the dose-response relationship of lansoprazole on ulcer healing and compared it with ranitidine in 314 out-patients with endoscopically assessed, symptomatic duodenal ulcer." | 9.07 | Dose-related healing of duodenal ulcer with the proton pump inhibitor lansoprazole. ( Barth, H; Dammann, HG; Hengels, KJ; Kleinert, R; Londong, W; Müller, P; Rohde, H; Simon, B, 1991) |
| "The aim was to compare the clinical efficacy of lansoprazole with the efficacies of ranitidine and famotidine in order to rank this drug in the hierarchy of duodenal ulcer treatments." | 8.79 | Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. ( Agostini, H; Lemaire, M; Poynard, T, 1995) |
| " Cysteamine inhibits the release of somatostatin and induces the formation of duodenal ulcers in rats." | 7.73 | Enhanced ghrelin secretion in rats with cysteamine-induced duodenal ulcers. ( Arakawa, M; Fukuhara, S; Hibi, T; Hosoda, H; Ishii, H; Kangawa, K; Kitajima, M; Masaoka, T; Minegishi, Y; Suzuki, H, 2005) |
| " Likewise, pantoprazole showed the healing promoting action on chronic duodenal ulcers induced by acetic acid, and this effect was also more potent when compared to omeprazole or lansoprazole." | 7.70 | Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. ( Kato, S; Konaka, A; Nishijima, M; Takeuchi, K; Yasuhiro, T, 1999) |
| "One-week therapy with lansoprazole, amoxicillin and clarithromycin is highly effective in duodenal ulcer healing and symptom improvement." | 7.69 | Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin and clarithromycin. ( Hentschel, E; Schütze, K, 1995) |
| "To study the efficiency of the combination lansoprazole and amoxicillin on the eradication of Helicobacter pylori and duodenal ulcer healing." | 7.69 | [Erradicating treatment of Helicobacter pylori with lansoprazole and amoxicillin in duodenal ulcer patients]. ( Aller, R; Alvarez Baleriola, I; Bermejo, F; Boixeda, D; Gisbert, JP; Martín de Argila, C, 1996) |
| " The optimal dosage and duration of treatment need to be specified." | 6.68 | Lansoprazole versus lansoprazole plus amoxicillin treatment for eradication of Helicobacter pylori in patients with gastric ulcer. ( Fujita, N; Hisano, K; Kobayashi, T; Kurokawa, I; Ochiai, T; Sugiyama, T; Yabana, T; Yachi, A, 1995) |
| "Lansoprazole 30 mg/day was administered to 124 gastric ulcer (GU) patients and 57 duodenal ulcer (DU) patients." | 6.68 | Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication. ( Kato, T; Ogoshi, K; Sakagawa, T, 1995) |
| "When lansoprazole alone was administered to the patients, H." | 6.68 | [Effect of treatment with lansoprazole and amoxicillin in combination on healing process of duodenal ulcer]. ( Maruyama, M, 1996) |
| "Time to ulcer recurrence was significantly longer (P < 0." | 6.68 | Prevention of duodenal ulcer recurrence with 15 mg lansoprazole: a double-blind placebo-controlled study. The Lansoprazole Study Group. ( Goff, J; Greski-Rose, P; Jennings, D; Jhala, N; Lanza, F; Silvers, D; Winters, J, 1997) |
| "Clinical experience with lansoprazole in the acute treatment of duodenal ulcer patients has been compared with treatment using placebo, H2-antagonists or omeprazole." | 6.17 | Acute treatment of duodenal ulcer: experience with lansoprazole. ( Mignon, M; Vallot, T, 1993) |
| " This study aimed to establish the noninferiority of keverprazan to lansoprazole in the treatment of patients with duodenal ulcer (DU)." | 5.69 | Efficacy and Safety of Keverprazan Compared With Lansoprazole in the Treatment of Duodenal Ulcer: A Phase III, Randomized, Double-Blind, Multicenter Trial. ( Chen, HH; Chen, HX; Chen, MH; Guo, QH; Li, FF; Li, SB; Li, X; Liao, AJ; Liu, CX; Liu, XW; Liu, YL; Miao, XP; Tan, ND; Tang, YP; Wu, H; Xia, M; Xiao, YL; Zhang, Y; Zhang, ZY, 2023) |
| "In this phase 3, randomized (1:1), double-blind, double-dummy, parallel-group, non-inferiority study (April 5, 2017, to July 19, 2019), patients with ≥ 1 endoscopically confirmed duodenal ulcer, at 52 hospitals (China, South Korea, and Taiwan), received vonoprazan 20 mg once daily (QD) or lansoprazole 30 mg QD for 6 weeks maximum." | 5.51 | Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients. ( Chiu, CT; Chong, CF; Chung, WC; Gu, L; Hou, X; Kudou, K; Meng, F; Sha, W; Wang, J; Zhang, S, 2022) |
| "Considering the limitation of varying acid suppression of proton pump inhibitors, this study was aimed to assess the efficacy, safety, and dose-effect relationship of keverprazan, a novel potassium-competitive acid blocker, in the treatment of duodenal ulcer (DU) compared with lansoprazole." | 5.51 | Efficacy of keverprazan for duodenal ulcer: A phase II randomized, double-blind, parallel-controlled trial. ( Chen, HH; Chen, MH; Deng, H; Du, SY; Huo, LJ; Li, SB; Li, X; Liao, AJ; Liu, CX; Liu, HL; Liu, XW; Peng, Q; Qi, LZ; Shen, PZ; Shi, RH; Shu, X; Tan, ND; Tuo, BG; Wang, BM; Wang, JN; Wang, QZ; Wu, H; Xiao, YL; Ye, B; Zhan, Q; Zhang, BQ; Zhang, GX; Zhang, ZY; Zhen, YB, 2022) |
| " Recurrent upper GI bleeding occurred in one patient receiving lansoprazole (duodenal ulcer) and three receiving famotidine (two gastric ulcers and one duodenal ulcer)." | 5.34 | Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial. ( Chan, FKL; Ching, JYL; Chiu, PWY; Lau, JYW; Lau, LHS; Ling, RHY; Tse, YK; Wong, GLH; Wong, VWS, 2020) |
| " lansoprazole, a proton pump inhibitor, for treatment of gastric ulcer (GU) or duodenal ulcer (DU)." | 5.24 | Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials. ( Miwa, H; Mori, Y; Nishimura, A; Sakaki, N; Sakurai, Y; Takanami, Y; Tatsumi, T; Uedo, N; Watari, J, 2017) |
| "Low-dose lansoprazole has not been intensively evaluated for its efficacy in the prevention of recurrent gastric or duodenal ulcers in patients receiving long-term non-steroidal anti-inflammatory drug (NSAID) therapy for pain relief in such diseases as rheumatoid arthritis, osteoarthritis, and low back pain." | 5.16 | Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. ( Asaka, M; Ashida, K; Hiraishi, H; Hiramatsu, N; Kanto, T; Katsuo, S; Kontani, T; Matsui, S; Mizokami, Y; Sakaki, N; Soen, S; Sugano, K; Takei, Y; Takeuchi, T, 2012) |
| "The efficacy of low-dose lansoprazole has not been established for the prevention of recurrent gastric or duodenal ulcers in those receiving long-term low-dose aspirin (LDA) for cardiovascular and cerebrovascular protection." | 5.15 | Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. ( Abe, S; Ashida, K; Chiba, T; Hiramatsu, N; Itabashi, T; Kanto, T; Matsui, S; Matsumoto, Y; Mizokami, Y; Sakaki, N; Shimada, K; Sugano, K; Uchiyama, S; Uemura, N, 2011) |
| "Subjects 18 years or older with osteoarthritis, without gastroduodenal ulcer or erosive esophagitis at baseline endoscopy, and a cardiovascular indication for prophylaxis low-dose (81 or 325 mg) aspirin were prescribed open-label aspirin and blindly randomized to celecoxib 200 mg/day or naproxen 500 mg twice daily plus lansoprazole 30 mg once daily." | 5.12 | Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. ( Amer, F; Cryer, B; Goldstein, JL; Hunt, B, 2007) |
| "This analysis compared the efficacy of misoprostol, lansoprazole, and placebo in reducing the risk of gastric or duodenal ulcer recurrence in patients taking NSAIDs and low-dose aspirin." | 5.11 | Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis. ( Amer, F; Christopoulos, NG; Goldstein, JL; Huang, B, 2004) |
| "Sixty-seven patients (49 with Zollinger-Ellison syndrome [ZES], 18 without), with basal acid output (BAO) >15 mmol/h or >5 mmol/h if post-antrectomy (n = 9, all ZES), were treated with individually optimized doses of lansoprazole (7." | 5.11 | Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. ( Hirschowitz, BI; Mohnen, J; Simmons, J, 2005) |
| "To compare the efficacy of lansoprazole and pantoprazole in treatment of active duodenal ulcer and Helicobacterpylori eradication." | 5.10 | In treatment of active duodenal ulcer and Helicobacter pylori eradication. ( Karaoglu, AO; Yasa, MH; Yukselen, V, 2003) |
| "To compare lansoprazole 30 mg once daily, lansoprazole 15 mg once daily and ranitidine 150 mg once nightly in the prevention of duodenal ulcer relapse in patients whose duodenal ulcers had been previously healed with lansoprazole 30 mg once daily or ranitidine 300 mg nightly." | 5.09 | Lansoprazole is superior to ranitidine as maintenance treatment for the prevention of duodenal ulcer relapse. ( Bardhan, KD; Crouch, SL; Crowe, J; Keeling, PN; Thompson, RP; Trewby, PN; Weir, D, 1999) |
| "Lansoprazole safely and effectively reduces duodenal ulcer recurrence and ulcer-related symptoms." | 5.09 | Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2-receptor antagonists. ( Campbell, D; Haber, M; Jennings, DE; Kovacs, TO; Richter, J; Rose, P, 1999) |
| "The aim of this randomized, multicenter, double-masked, parallel-group study was to compare the efficacy of lansoprazole with that of omeprazole monotherapy in duodenal ulcer healing and prevention of relapse." | 5.09 | Lansoprazole versus omeprazole for duodenal ulcer healing and prevention of relapse: a randomized, multicenter, double-masked trial. ( Dobrilla, G; Fiocca, R; Piazzi, L, 1999) |
| "A health economic evaluation of triple therapy with lansoprazole, amoxicillin and clarithromycin versus 2 dual therapies (lansoprazole or omeprazole, each with amoxicillin) in the eradication of Helicobacter pylori in patients with duodenal ulcers was performed in parallel with a randomised clinical trial." | 5.09 | Cost effectiveness of Helicobacter pylori eradication therapies in patients with duodenal ulcer. An analysis of triple therapy versus two dual therapy alternatives. ( Norinder, A; Ohlin, B; Tennvall, GR, 1999) |
| "To compare two lansoprazole-based non-clarithromycin triple therapies and one dual therapy in a prospective double-blind placebo-controlled study of Helicobacter pylori eradication and duodenal ulcer healing." | 5.09 | Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. ( Carpio, RE; Fock, KM; Ho, J; Hu, FL; Hu, PJ; Huang, NX; Kachintorn, U; Kullavanijaya, P; Lam, SK; Lesmana, L; Li, YY; Manan, C; Perez, JY; Phornphutkul, K; Qian, SC; Wong, BC; Xiao, SD, 2000) |
| "The primary objective of the present study was to evaluate the efficacy of 30 and 60 mg of lansoprazole administered in combination with two antibiotics for 7 or 10 days in eradicating Helicobacter pylori in duodenal ulcer patients." | 5.09 | [Treatment of Helicobacter pylori infection with lansoprazole 30 mg or 60 mg combined with two antibiotics for duodenal ulcers]. ( Joubert-Collin, M; Lamouliatte, H; Perie, F, 2000) |
| "The aim of this study was to compare in an open, controlled and prospective trial the efficacy of one-week regimen using either lansoprazole (2 x 30 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group I, 60 cases) or ranitidine bismuth citrate (2 x 400 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group II, 61 cases) on the eradication of Hp infection in duodenal ulcer patients." | 5.09 | [Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer]. ( Buzás György, M; Illyés, G; Székely, E; Széles, I, 2000) |
| " Patients with gastric ulcer (GU) or duodenal ulcer (DU) were enrolled in this study; 583 eligible patients (GU, 325; DU, 258) were administered lansoprazole (30 mg/day for 8 weeks for GU, and the same dosage for 6 weeks for DU) as first-line therapy, and a half dose of H2RA as maintenance therapy for 12 months." | 5.09 | Peptic ulcer recurrence during maintenance therapy with H2-receptor antagonist following first-line therapy with proton pump inhibitor. ( Asaka, M; Asaki, S; Ashida, K; Harasawa, S; Hoshihara, Y; Kajiyama, G; Kaneko, E; Kobayashi, K; Muto, Y; Nakamura, T; Nakazawa, S; Ogawa, N; Sakaki, N; Takemoto, T; Yao, T, 2000) |
| " Fifty patients with active or scarred duodenal ulcer were randomized to lansoprazole or omeprazole for 1 to 4 weeks, with clarithromycin 250 mg twice a day and tinidazole 500 mg twice a day for the first week." | 5.09 | Long-term follow-up and serologic assessment after triple therapy with omeprazole or lansoprazole of Helicobacter-associated duodenal ulcer. ( Fanti, L; Guslandi, M; Ieri, R; Mezzi, G; Passaretti, S; Testoni, PA, 2001) |
| " pylori-positive duodenal ulcers were randomized to receive either lansoprazole 30 mg, clarithromycin 500 mg, and metronidazole 400 mg twice daily for 7 days (LCM-7) or lansoprazole 30 mg, clarithromycin 500 mg, metronidazole 400 mg, and bismuth subcitrate 240 mg twice daily for 3 days (LCMB-3)." | 5.09 | Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study. ( Chan, CK; Chu, KM; Fung, FM; Hu, FL; Hu, WH; Hui, WM; Kung, NN; Lai, KC; Lam, SK; Lau, GK; Liu, XG; Wang, WH; Wong, BC; Wong, WM; Yuen, MF, 2001) |
| "This study was undertaken to compare the efficacy of lansoprazole (LAN)-based triple therapy with that of RBC-based dual therapy in H pylori-infected patients with duodenal ulcer." | 5.09 | Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study. ( Belmonte, A; Cavaliere, C; Ciliberto, E; Fiocca, R; Frandina, C; Giglio, A; Luzza, F; Pallone, F; Saccà, N; Trimboli, V, 2001) |
| "To investigate Helicobacter pylori eradication in duodenal ulcer patients with a new regimen, lansoprazole 30 mg daily for one or four weeks plus twice daily tetracycline 500 mg, clarithromycin 250 mg, and metronidazole 400 mg." | 5.09 | Quadruple therapy for symptomatic spontaneous duodenal ulcer disease. ( Bateson, MC, 2001) |
| "To compare the efficacy of one-week versus two-week treatment with lansoprazole, amoxycillin and clarithromycin in inducing healing of Helicobacter pylori-positive duodenal ulcers as well as to investigate the role of several factors, determinant in the ulcer healing process." | 5.09 | Prolonging proton pump inhibitor-based anti-Helicobacter pylori treatment from one to two weeks in duodenal ulcer: is it worthwhile? ( Bianchi Porro, G; Cucino, C; Imbesi, V; Maconi, G; Russo, A, 2000) |
| " pylori positive duodenal ulcer were enrolled and randomly allocated into one of the five treatment groups: 1) group A: received lansoprazole 30 mg once daily for 2 weeks plus amoxicillin (AM) 500 mg and metronidazole (MZ) 500 mg twice daily for one week in the first week; 2) group B: the AM in group A was replaced by clarithromycin (CM) 250 mg; 3) group C: the MZ in group A was replaced by CM 250 mg; 4) group D: the AM and CM in group C was used for 2 wk; 5) group E: the CM in group D was doubled to 500 mg twice daily." | 5.09 | A multicenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy. ( Hsu, CT; Kuo, CF; Wang, CS; Wang, TH; Yang, JC; Yang, KC, 1999) |
| "Satisfactory antral biopsies were obtained from 119 duodenal ulcer patients before and after 4 wk of therapy with lansoprazole, ranitidine, or placebo." | 5.08 | The effects of short-term lansoprazole therapy on Helicobacter pylori infection and antral gastritis in duodenal ulcer patients. ( Atkinson, BF; Brightman, SA; Jhala, NC; McFarland, MM; Morale, B; Rubin, W, 1995) |
| "A randomized, single-blind study was designed to assess the effect of lansoprazole alone and lansoprazole plus amoxicillin on the healing and eradication rates in Helicobacter pylori-associated peptic ulcer disease." | 5.08 | Clinical efficacy of lansoprazole in eradication of Helicobacter pylori. ( Asaka, M; Kagaya, H; Katagiri, M; Katoh, M; Kudoh, M; Takeda, H, 1995) |
| "This study reports preliminary results of a controlled, multicenter trial on the quality of ulcer healing induced by lansoprazole (LPZ) or roxatidine (R) in gastric ulcer (GU) or duodenal ulcer (DU) patients." | 5.08 | Quality of peptic ulcer healing induced by lansoprazole and roxatidine. ( Fujino, MA; Kobayashi, K; Morozumi, A; Ohtsuka, H; Sano, S; Suzuki, Y; Tachikawa, H; Uchida, N; Ueda, F; Yamamoto, Y, 1995) |
| "The clinical usefulness of lansoprazole in the healing of gastric and duodenal ulcers, the S2-stage shift rate (white scarring rate), and endoscopic healing rate with respect to degree of gastric mucosal atrophy were investigated." | 5.08 | Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group. ( Asaki, S; Hongo, M; Sakurada, H; Sato, A; Takeda, T; Toyota, T, 1995) |
| "In the present study, the effects of short-term treatment with lansoprazole on healing and recurrence of peptic ulcer were investigated." | 5.08 | The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody. ( Akimoto, K; Fukujin, H; Katoaka, A; Mashima, H; Mine, T; Nagasawa, J; Tajima, A; Takano, T; Tsuchida, T; Yasuda, H, 1995) |
| "In this double-blind randomized comparative study patients with active duodenal ulcers were treated with either 30 mg lansoprazole or 20 mg omeprazole in the morning." | 5.08 | Lansoprazole versus omeprazole in active duodenal ulcer. A double-blind, randomized, comparative study. ( Anker-Hansen, O; Carling, L; Ekström, P; Sellström, H; Sjöstedt, S; Unge, P, 1995) |
| "A double-blind, multicentre study was undertaken in 296 patients with endoscopically proven duodenal ulcer to compare the efficacy and safety of lansoprazole 15, 30 or 60 mg with placebo." | 5.08 | A comparison of three doses of lansoprazole (15, 30 and 60 mg) and placebo in the treatment of duodenal ulcer. The Lansoprazole Study Group. ( Avner, DL; Dorsch, ER; Greski-Rose, PA; Jennings, DE, 1995) |
| "To evaluate the efficacy of a second generation acid pump inhibitor-lansoprazole (L) a controlled clinical trial in 72 patients of duodenal ulcer was carried out with omeprazole (O) as control." | 5.08 | [A clinical trial of lansoprazole in the treatment of duodenal ulcer]. ( Chen, S; Pei, Y; Wang, B, 1995) |
| " pylori-positive duodenal ulcer were randomly assigned to receive one of the following three antiulcer regimens: (1) lansoprazole 30 mg b." | 5.08 | Comparison of two lansoprazole-antibiotic combinations (amoxycillin or classical triple therapy) for treatment of H. pylori infection in duodenal ulcer patients. ( Bargiggia, S; Bianchi Porro, G; Colombo, E; Maconi, G; Parente, F, 1996) |
| "We report long-term, up to 4 years, prospective treatment using lansoprazole in nine male patients with duodenal ulcers and a BAO of more than 15 mmol/h whose results are compared with those in 10 male Zollinger-Ellison syndrome patients with intact stomachs reported in detail in an accompanying paper." | 5.08 | Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h. ( Hirschowitz, BI; Mohnen, J; Shaw, S, 1996) |
| " pylori-positive gastritis with or without peptic ulcer, and compared with the classic 'Bazzoli regimen' (OCT: omeprazole, clarithromycin, tinidazole) in 60 matched patients." | 5.08 | Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori. ( Alvisi, V; Caselli, M; Gasbarrini, G; Gaudenzi, P; Luzzi, I; Ruina, M; Sartori, S; Trevisani, L; Tursi, A, 1997) |
| "Eighty patients with endoscopically proven active duodenal ulcer were randomized to take ranitidine or lansoprazole for 4-8 wk, together with clarithromycin 250 mg b." | 5.08 | Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer. ( Bargiggia, S; Bianchi Porro, G; Lazzaroni, M, 1997) |
| " pylori-infected patients with endoscopically documented duodenal ulcer either currently or within the past year were randomized to 14 days of (1) lansoprazole, 30 mg bid, plus amoxicillin, 1 gm tid; (2) lansoprazole, 30 mg tid, plus amoxicillin, 1 gm tid; (3) lansoprazole, 30 mg tid alone; or (4) amoxicillin, 1 gm tid alone." | 5.08 | Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection. ( Arora, A; Graham, D; Haber, M; Harford, W; Lanza, F; Rose, P; Siepman, N; Weissfeld, A, 1996) |
| " The aim of the present study was to assess efficacy and tolerability of the proton pump inhibitors lansoprazole given at bedtime as compared to ranitidine, both in acute and maintenance treatment of duodenal ulcer." | 5.08 | Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial. ( Dattilo, M; Russo, A, 1997) |
| "In patients with active or a recent history of duodenal ulcer, a 14-day course of lansoprazole-based triple therapy without additional acid suppression therapy is highly effective in the eradication of H." | 5.08 | Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. ( Freston, J; Haber, M; Krause, R; Rose, P; Sahba, B; Schwartz, H; Siepman, N; Weissfeld, A, 1998) |
| " Fasting had no influence on the result of duodenal ulcer treatment by lansoprazole which was well tolerated." | 5.08 | [Effect of the observance of diurnal fast of Ramadan on duodenal ulcer healing with lansoprazole. Results of a prospective controlled study]. ( Ajmi, S; Mehdi, A, 1997) |
| "In order to explore the optimal regimens for the eradication of Helicobacter pylori (Hp), eighty-eight patients with duodenal ulcer (DU) or non-ulcer dyspepsia and Hp infection, defined by culture and histology, received the one-week triple therapy with clarithromycin (Cla), furazolidone (Fur) plus lansoprazole (Lan) or colloidal bismuth subcitrate (CBS)." | 5.08 | [Clarithromycin combined short-term triple therapies for eradication of Helicobacter pylori infection]. ( Liu, W; Lü, B; Xiao, S, 1996) |
| " Patients with duodenal ulcer were treated with lansoprazole alone (n = 11) or lansoprazole and amoxycillin (n = 12)." | 5.08 | Amount of Helicobacter pylori in gastric mucus during anti-H. pylori treatment. ( Arai, H; Furuta, T; Futami, H; Hanai, H; Kaneko, E; Takashima, M, 1998) |
| " pylori-infected duodenal ulcer patients we investigated the gastritis parameters in antral and corpus mucosa before treatment, after 6 and 12 months of therapy, and 6 months after termination of treatment with 15 mg lansoprazole or 150 mg ranitidine/day." | 5.08 | Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. ( Kiel, G; Meining, A; Stolte, M, 1998) |
| "Sixty patients with active duodenal ulcers who tested positive for the rapid urease test had a C-14 UBT at 0 weeks (at enrollment) and at 6 and 12 weeks using 5 microCi (185 KBq) of C-14 urea." | 5.08 | Can the C-14 urea breath test replace follow-up endoscopic biopsies in patients treated for Helicobacter pylori infection? ( Ahuja, V; Bal, CS; Sharma, MP, 1998) |
| "In order to investigate whether chronic duodenal ulcer disease is a consequence of disturbed mucosal turnover and growth factor expression, we studied 16 patients with duodenal ulcers before, during, and after endoscopic healing with lansoprazole or sucralfate." | 5.08 | Effect of chronic duodenal ulceration and its treatment with lanzoprazole or sucralfate on gastroduodenal mucosal protein turnover and TGF-alpha, bFGF, and EGF receptor expression in humans. ( Marks, IN; O'Keefe, SJ; Ogden, J; Winter, T; Zhang, T, 1998) |
| "To study in a double-blind controlled manner the effects of lansoprazole 15 mg or 30 mg daily compared with ranitidine 300 mg once daily and placebo in the relieving of symptoms and healing of acute duodenal ulceration." | 5.07 | Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Lansoprazole Study Group. ( Goff, J; Greski-Rose, P; Jennings, D; Lanza, F; Scowcroft, C, 1994) |
| "The purpose of this study was to compare duodenal ulcer healing, symptom relief, and safety of lansoprazole (a new proton pump inhibitor) given at doses of 30 mg and 60 mg, in the morning with ranitidine 300 mg at bedtime." | 5.07 | Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine. ( Bardhan, KD; Christian, J; Cochran, KM; Hawkey, CJ; Long, RG; Moules, IK; Wormsley, KG, 1993) |
| "The efficacy of lansoprazole (30 mg/d) and omeprazole (20 mg/d) has been assessed in active duodenal ulcer disease in 144 patients included in a multicentric, randomized, double-blind trial." | 5.07 | [Comparison of lansoprazole (30 mg) and omeprazole (20 mg) in the treatment of duodenal ulcer. A multicenter double-blind comparative trial]. ( Andrieu, J; Coste, T; Dupuis, J; Grimaud, JC; Julien, H; Lemerez, M; Licht, H; Petite, JP; Sallerin, V; Slama, JL, 1993) |
| "Forty-two patients with peptic ulceration of the duodenum, stomach or oesophagus, who had not responded to 3 or more months of high-dose treatment with ranitidine (450 or 600 mg/day), were treated with oral lansoprazole at 30-60 mg daily." | 5.07 | An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. ( Arnold, R; Brunner, G; Fuchs, W; Hennig, U, 1993) |
| " Double-blind comparative studies with a beta-blocker, famotidine, in gastric ulcer (study 1) and in duodenal ulcer (study 2) were conducted." | 5.07 | [Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer]. ( Ogawa, N, 1992) |
| " In this 2:1 randomized, double-blind, multicentre trial lansoprazole 30 mg am was compared to 40 mg famotidine nocte in 264 out-patients suffering from uncomplicated duodenal ulcer." | 5.07 | Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration. ( Grymbowski, T; Hennig, U; Hotz, J; Kleinert, R; Schwarz, JA, 1992) |
| " This randomized, double-blind multicentre trial studied the dose-response relationship of lansoprazole on ulcer healing and compared it with ranitidine in 314 out-patients with endoscopically assessed, symptomatic duodenal ulcer." | 5.07 | Dose-related healing of duodenal ulcer with the proton pump inhibitor lansoprazole. ( Barth, H; Dammann, HG; Hengels, KJ; Kleinert, R; Londong, W; Müller, P; Rohde, H; Simon, B, 1991) |
| "The proton pump inhibitors (PPIs) lansoprazole (LPZ) and omeprazole (OPZ) have been widely used for more than 20 years in the treatment of acid-related diseases such as gastro-duodenal ulcers and reflux esophagitis." | 4.89 | Discovery of lansoprazole and its unique pharmacological properties independent from anti-secretory activity. ( Satoh, H, 2013) |
| "An 11-year-old boy with Helicobacter pylori-associated duodenal ulcer was successfully treated with a combination of lansoprazole, amoxicillin, and clarithromycin." | 4.82 | Helicobacter heilmannii infection in a child after successful eradication of Helicobacter pylori: case report and review of literature. ( Iinuma, K; Kato, S; Minoura, T; Ohyauchi, M; Ozawa, K; Sekine, H; Shimosegawa, T, 2005) |
| " Although PPIs have been introduced into the therapy of acute peptic ulcer disease at different daily, oral doses of 20 mg (omeprazole and rabeprazole), 30 mg (lansoprazole) and 40 mg (pantoprazole), the data suggest that the optimal dose of lansoprazole, omeprazole and pantoprazole, with respect to the acute treatment of peptic ulcers and moderate to severe gastroesophageal reflux disease (GERD), is about 30-40 mg daily." | 4.80 | Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. ( Horbach, S; Kromer, W; Lühmann, R, 1999) |
| "The aim was to compare the clinical efficacy of lansoprazole with the efficacies of ranitidine and famotidine in order to rank this drug in the hierarchy of duodenal ulcer treatments." | 4.79 | Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. ( Agostini, H; Lemaire, M; Poynard, T, 1995) |
| " In the treatment of gastric ulcer, analysis of all studies that have compared lansoprazole, a newly developed proton pump inhibitor, and H2-receptor antagonists has shown a statistically significant difference for a higher healing rate with lansoprazole." | 4.78 | Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer. ( Florent, C, 1993) |
| " There are the results of studies in which the known quantitative parameters of duodenal reflux in the duodenal ulcer patients were simulated to identify their influence on the disintegration of enterosoluble dosage forms and the bioavailability of proton pump inhibitors (in healthy volunteers, patients with gasritis, exacerbation and remission of peptic ulcer disease the pharmacokinetics of lansoprazole, intragastric pH-metry with floating capsule for teleradio-pH-metry were investigated, and in an in vitro study the dissolution tests of proton pump inhibitors with pH 3 and pH = 4 were made)." | 3.81 | [THE FEATURES OF SECRETION AND STOMACH MOTOR PROCESSES IN PATIENTS WITH DUODENAL ULCERS AS A CAUSE FOR REDUCING BIOAVAILABILITY OF PROTON PUMP INHIBITORS]. ( Prokofiev, AB; Serebrova, SY; Zhuravleva, MV, 2015) |
| "Lansoprazole is an effective acid pump inhibitor acting at the final enzymatic step of the acid secretory pathway of the parietal cell, decreasing gastric acid secretion regardless of the primary stimulus." | 3.77 | Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. ( Barradell, LB; Faulds, D; McTavish, D, 1992) |
| " Cysteamine inhibits the release of somatostatin and induces the formation of duodenal ulcers in rats." | 3.73 | Enhanced ghrelin secretion in rats with cysteamine-induced duodenal ulcers. ( Arakawa, M; Fukuhara, S; Hibi, T; Hosoda, H; Ishii, H; Kangawa, K; Kitajima, M; Masaoka, T; Minegishi, Y; Suzuki, H, 2005) |
| "Biopsy specimens were taken from the duodenal ulcer patients who underwent gastroscopy before and after the treatment of Lansoprazole." | 3.73 | [Distribution of Helicobacter pylori in stomach before and after the administration of Lansoprazole]. ( Cheng, HY; Dong, XY; Jin, Z; Lin, SR; Ye, SM; Zhou, LY, 2005) |
| " pylori infection who had gastritis, duodenal ulcer (DU) or gastric ulcer (GU) received 1 week's triple therapy of lansoprazole 30 g once daily (OD), amoxycillin 250 mg qid and clarithromycin 250 mg tid." | 3.72 | Low dose, one-week triple therapy (lanzoprazole, amoxycillin, clarithromycin) for eradication of Helicobacter pylori infection. ( Uthaisaengsook, W, 2003) |
| "Gastric juice pH, ammonia concentration in gastric juice, serum gastrin level, and grade of gastritis in accordance with the Sydney System were determined for patients with gastric ulcer (GU) and duodenal ulcer (DU) before and after treatment with lansoprazole and amoxicillin, and results were compared with those of H." | 3.70 | Effect of Helicobacter pylori infection on gastric juice pH. ( Arai, H; Baba, S; Furuta, T; Futami, H; Hanai, H; Kajimura, M; Kaneko, E; Takashima, M, 1998) |
| " Likewise, pantoprazole showed the healing promoting action on chronic duodenal ulcers induced by acetic acid, and this effect was also more potent when compared to omeprazole or lansoprazole." | 3.70 | Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. ( Kato, S; Konaka, A; Nishijima, M; Takeuchi, K; Yasuhiro, T, 1999) |
| "To evaluate endogenous and exogenous factors affecting the quality of ulcer healing produced by proton pump inhibitors, gastric acid pH, serum gastrin, and serum pepsinogen (PG) I and II were measured in peptic ulcer patients before and after treatment with lansoprazole 30 mg once daily." | 3.69 | Factors affecting quality of ulcer healing after lansoprazole treatment. ( Hanai, H; Ito, G; Kaneko, E; Nakagawara, M; Nawano, M; Ooi, S; Watanabe, F, 1995) |
| "One-week therapy with lansoprazole, amoxicillin and clarithromycin is highly effective in duodenal ulcer healing and symptom improvement." | 3.69 | Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin and clarithromycin. ( Hentschel, E; Schütze, K, 1995) |
| "To study the efficiency of the combination lansoprazole and amoxicillin on the eradication of Helicobacter pylori and duodenal ulcer healing." | 3.69 | [Erradicating treatment of Helicobacter pylori with lansoprazole and amoxicillin in duodenal ulcer patients]. ( Aller, R; Alvarez Baleriola, I; Bermejo, F; Boixeda, D; Gisbert, JP; Martín de Argila, C, 1996) |
| "The 1-week triple therapy was safe and effective for eradicating H." | 2.69 | Safety and efficacy of one-week triple therapy for eradicating Helicobacter pylori in children. ( Asaka, M; Iinuma, K; Kato, S; Ohnuma, K; Ritsuno, H; Sugiyama, T, 1998) |
| " The optimal dosage and duration of treatment need to be specified." | 2.68 | Lansoprazole versus lansoprazole plus amoxicillin treatment for eradication of Helicobacter pylori in patients with gastric ulcer. ( Fujita, N; Hisano, K; Kobayashi, T; Kurokawa, I; Ochiai, T; Sugiyama, T; Yabana, T; Yachi, A, 1995) |
| "Lansoprazole 30 mg/day was administered to 124 gastric ulcer (GU) patients and 57 duodenal ulcer (DU) patients." | 2.68 | Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication. ( Kato, T; Ogoshi, K; Sakagawa, T, 1995) |
| "pylori infection and the ulcer recurrence rate after 1 year were investigated." | 2.68 | Effects of lansoprazole plus amoxycillin on the cure of Helicobacter pylori infection in Japanese peptic ulcer patients. ( Asaka, M; Hokari, K; Kagaya, H; Katagiri, M; Kato, M; Koshiyama, T; Kudo, M; Nishikawa, K; Sugiyama, T; Sukegawa, M; Takeda, H, 1996) |
| "When lansoprazole alone was administered to the patients, H." | 2.68 | [Effect of treatment with lansoprazole and amoxicillin in combination on healing process of duodenal ulcer]. ( Maruyama, M, 1996) |
| "Time to ulcer recurrence was significantly longer (P < 0." | 2.68 | Prevention of duodenal ulcer recurrence with 15 mg lansoprazole: a double-blind placebo-controlled study. The Lansoprazole Study Group. ( Goff, J; Greski-Rose, P; Jennings, D; Jhala, N; Lanza, F; Silvers, D; Winters, J, 1997) |
| "His only medical history was mild Alzheimer's disease diagnosed 6 months prior." | 2.52 | Upper gastrointestinal bleed associated with cholinesterase inhibitor use. ( Kok, KS; Loke, Y; Southgate, J, 2015) |
| "Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion in a dose-dependent manner via inhibition of H+/K+-adenosine triphosphatase in gastric parietal cells." | 2.41 | An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole. ( Bown, RL, 2002) |
| "When lansoprazole was used as monotherapy, the mean Hp eradication was 6% in four studies." | 2.39 | Adjuvant therapy for Helicobacter pylori eradication: role of lansoprazole in clinical studies. ( Lamouliatte, H, 1995) |
| "Gastric metaplasia was endoscopically and histologically evaluated before and after eradication of this bacterium." | 1.32 | Long-term follow-up of gastric metaplasia after eradication of Helicobacter pylori. ( Sano, T; Urakami, Y, 2003) |
| "Lactoferrin (Lf) is an iron-binding glycoprotein present in milk, lacrimae, saliva, and gastroduodenal secretions." | 1.30 | Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation. ( Ikemura, N; Imoto, I; Misaki, M; Nakao, K; Shibata, T; Taguchi, Y; Takaji, S; Yamauchi, K; Yamazaki, N, 1997) |
| "Lansoprazole was mostly prescribed in patients with reflux oesophagitis (55." | 1.30 | A prospective follow-up study of 5669 users of lansoprazole in daily practice. ( Claessens, A; Heerdink, E; Lamers, CB; Leufkens, H; van Eijk, J, 1997) |
| "Lansoprazole has a cytotoxic action against this organism, the MIC being 2." | 1.29 | Effect of lansoprazole in mono-, dual-, or triple therapy on Helicobacter pylori eradication. ( Kawano, S; Murakami, M; Saita, H; Tsuji, S, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.67) | 18.7374 |
| 1990's | 93 (62.00) | 18.2507 |
| 2000's | 44 (29.33) | 29.6817 |
| 2010's | 8 (5.33) | 24.3611 |
| 2020's | 4 (2.67) | 2.80 |
| Authors | Studies |
|---|---|
| Hou, X | 1 |
| Meng, F | 1 |
| Wang, J | 1 |
| Sha, W | 1 |
| Chiu, CT | 1 |
| Chung, WC | 1 |
| Gu, L | 1 |
| Kudou, K | 1 |
| Chong, CF | 1 |
| Zhang, S | 1 |
| Tan, ND | 2 |
| Liu, XW | 2 |
| Liu, CX | 2 |
| Li, SB | 2 |
| Chen, HH | 2 |
| Li, X | 2 |
| Wu, H | 2 |
| Liao, AJ | 2 |
| Zhen, YB | 1 |
| Shen, PZ | 1 |
| Huo, LJ | 1 |
| Liu, HL | 1 |
| Shi, RH | 1 |
| Zhang, BQ | 1 |
| Zhang, ZY | 2 |
| Wang, JN | 1 |
| Zhan, Q | 1 |
| Deng, H | 1 |
| Shu, X | 1 |
| Tuo, BG | 1 |
| Wang, QZ | 1 |
| Du, SY | 1 |
| Qi, LZ | 1 |
| Zhang, GX | 1 |
| Peng, Q | 1 |
| Wang, BM | 1 |
| Ye, B | 1 |
| Chen, MH | 2 |
| Xiao, YL | 2 |
| Miao, XP | 1 |
| Li, FF | 1 |
| Guo, QH | 1 |
| Tang, YP | 1 |
| Xia, M | 1 |
| Liu, YL | 1 |
| Chen, HX | 1 |
| Zhang, Y | 1 |
| Wong, GLH | 1 |
| Lau, LHS | 1 |
| Ching, JYL | 1 |
| Tse, YK | 1 |
| Ling, RHY | 1 |
| Wong, VWS | 1 |
| Chiu, PWY | 1 |
| Lau, JYW | 1 |
| Chan, FKL | 1 |
| Sakaki, N | 5 |
| Ashida, K | 5 |
| Mizokami, Y | 3 |
| Chiba, T | 2 |
| Matsui, S | 3 |
| Kanto, T | 3 |
| Uemura, N | 2 |
| Hiramatsu, N | 3 |
| Sugano, K | 3 |
| Kok, KS | 1 |
| Loke, Y | 1 |
| Southgate, J | 1 |
| Serebrova, SY | 1 |
| Zhuravleva, MV | 1 |
| Prokofiev, AB | 1 |
| Miwa, H | 1 |
| Uedo, N | 1 |
| Watari, J | 1 |
| Mori, Y | 1 |
| Sakurai, Y | 1 |
| Takanami, Y | 1 |
| Nishimura, A | 1 |
| Tatsumi, T | 1 |
| Pellicano, R | 1 |
| Inoue, M | 1 |
| Okada, H | 1 |
| Hori, S | 1 |
| Kawahara, Y | 1 |
| Kawano, S | 2 |
| Takenaka, R | 1 |
| Toyokawa, T | 1 |
| Onishi, Y | 1 |
| Shiratori, Y | 1 |
| Yamamoto, K | 1 |
| Matsumoto, Y | 1 |
| Itabashi, T | 1 |
| Abe, S | 1 |
| Shimada, K | 1 |
| Uchiyama, S | 1 |
| Kontani, T | 1 |
| Katsuo, S | 1 |
| Takei, Y | 1 |
| Asaka, M | 6 |
| Soen, S | 1 |
| Takeuchi, T | 1 |
| Hiraishi, H | 1 |
| Satoh, H | 2 |
| Ishibashi, S | 1 |
| Iwakiri, R | 1 |
| Shimoda, R | 1 |
| Ootani, H | 1 |
| Kawasaki, S | 1 |
| Tadano, J | 1 |
| Kikkawa, A | 1 |
| Ootani, A | 1 |
| Oda, K | 1 |
| Fujise, T | 1 |
| Yoshida, T | 1 |
| Tsunada, S | 1 |
| Sakata, H | 1 |
| Fujimoto, K | 1 |
| Boon, YH | 1 |
| Vu, C | 1 |
| Kaushik, S | 1 |
| Cheng, CS | 1 |
| Chiu, TC | 1 |
| Chian, LC | 1 |
| Murakami, K | 1 |
| Sato, R | 1 |
| Okimoto, T | 1 |
| Nasu, M | 1 |
| Fujioka, T | 1 |
| Kodama, M | 1 |
| Kagawa, J | 1 |
| Sato, S | 1 |
| Abe, H | 1 |
| Arita, T | 1 |
| Cherniakevich, SA | 1 |
| Babkova, IV | 1 |
| Mikhalev, AI | 1 |
| Urakami, Y | 2 |
| Sano, T | 1 |
| Fedele, E | 1 |
| Lai, YC | 1 |
| Wang, TH | 2 |
| Huang, SH | 1 |
| Yang, SS | 1 |
| Wu, CH | 1 |
| Chen, TK | 1 |
| Lee, CL | 1 |
| Kamiya, T | 1 |
| Kobayashi, Y | 1 |
| Misu, N | 1 |
| Hirako, M | 1 |
| Adachi, H | 1 |
| Nagao, T | 1 |
| Shikano, M | 1 |
| Matsuhisa, E | 1 |
| Ando, T | 1 |
| Kimura, G | 1 |
| Uthaisaengsook, W | 1 |
| Chaudhary, A | 1 |
| Ahuja, V | 3 |
| Bal, CS | 2 |
| Das, B | 1 |
| Pandey, RM | 1 |
| Sharma, MP | 4 |
| Tiesmeier, J | 1 |
| Hinner, H | 1 |
| Kraus, J | 1 |
| Schuppert, F | 1 |
| Yukselen, V | 1 |
| Yasa, MH | 1 |
| Karaoglu, AO | 1 |
| Goldstein, JL | 2 |
| Huang, B | 1 |
| Amer, F | 2 |
| Christopoulos, NG | 1 |
| Hirschowitz, BI | 2 |
| Simmons, J | 1 |
| Mohnen, J | 2 |
| Arkkila, PE | 1 |
| Seppälä, K | 1 |
| Kosunen, TU | 1 |
| Sipponen, P | 1 |
| Mäkinen, J | 1 |
| Rautelin, H | 1 |
| Färkkilä, M | 1 |
| Kato, S | 3 |
| Ozawa, K | 1 |
| Sekine, H | 1 |
| Ohyauchi, M | 1 |
| Shimosegawa, T | 1 |
| Minoura, T | 1 |
| Iinuma, K | 2 |
| Fukuhara, S | 1 |
| Suzuki, H | 4 |
| Masaoka, T | 1 |
| Arakawa, M | 1 |
| Hosoda, H | 1 |
| Minegishi, Y | 1 |
| Kangawa, K | 1 |
| Ishii, H | 4 |
| Kitajima, M | 1 |
| Hibi, T | 3 |
| Jin, Z | 1 |
| Dong, XY | 1 |
| Lin, SR | 1 |
| Ye, SM | 1 |
| Zhou, LY | 1 |
| Cheng, HY | 1 |
| Güliter, S | 1 |
| Keleş, H | 1 |
| Ozkurt, ZN | 1 |
| Cengiz, DU | 1 |
| Kolukisa, E | 1 |
| Shiwani, MH | 1 |
| Cryer, B | 1 |
| Hunt, B | 1 |
| Dam, C | 1 |
| Bygum, A | 1 |
| Ahmed, W | 1 |
| Ali, A | 1 |
| Qureshi, H | 1 |
| Zuberi, SJ | 1 |
| Shamsi, ZU | 1 |
| Jhala, NC | 1 |
| McFarland, MM | 1 |
| Brightman, SA | 1 |
| Morale, B | 1 |
| Rubin, W | 1 |
| Atkinson, BF | 1 |
| Sugiyama, T | 3 |
| Hisano, K | 1 |
| Ochiai, T | 1 |
| Fujita, N | 1 |
| Kobayashi, T | 1 |
| Yabana, T | 1 |
| Kurokawa, I | 1 |
| Yachi, A | 1 |
| Katoh, M | 1 |
| Kudoh, M | 1 |
| Kagaya, H | 2 |
| Katagiri, M | 2 |
| Takeda, H | 2 |
| Furuta, T | 5 |
| Futami, H | 4 |
| Arai, H | 4 |
| Hanai, H | 5 |
| Kaneko, E | 7 |
| Takimoto, T | 1 |
| Ido, K | 1 |
| Taniguchi, Y | 1 |
| Satoh, K | 1 |
| Saifuku, K | 1 |
| Kihira, K | 2 |
| Yoshida, Y | 1 |
| Kimura, K | 1 |
| Nakata, H | 1 |
| Itoh, H | 1 |
| Nishioka, S | 1 |
| Shirai, T | 1 |
| Takagi, A | 1 |
| Kurumada, T | 1 |
| Ohta, U | 1 |
| Kobayashi, H | 1 |
| Harasawa, S | 2 |
| Miwa, T | 1 |
| Fujino, MA | 1 |
| Morozumi, A | 1 |
| Kobayashi, K | 2 |
| Ueda, F | 1 |
| Suzuki, Y | 1 |
| Uchida, N | 1 |
| Tachikawa, H | 1 |
| Sano, S | 1 |
| Ohtsuka, H | 1 |
| Yamamoto, Y | 1 |
| Asaki, S | 2 |
| Sato, A | 1 |
| Sakurada, H | 1 |
| Takeda, T | 1 |
| Hongo, M | 1 |
| Toyota, T | 1 |
| Sakaguchi, M | 1 |
| Tanaka, M | 1 |
| Takiuchi, H | 1 |
| Egashira, Y | 1 |
| Katsu, K | 1 |
| Ito, G | 1 |
| Nakagawara, M | 1 |
| Watanabe, F | 1 |
| Ooi, S | 1 |
| Nawano, M | 1 |
| Hoshino, E | 1 |
| Umeda, N | 1 |
| Sano, J | 1 |
| Miki, K | 1 |
| Yahagi, N | 1 |
| Oka, M | 1 |
| Kimura, M | 2 |
| Miyashita, H | 1 |
| Mine, T | 2 |
| Yasuda, H | 1 |
| Akimoto, K | 1 |
| Katoaka, A | 1 |
| Mashima, H | 1 |
| Tajima, A | 1 |
| Fukujin, H | 1 |
| Tsuchida, T | 1 |
| Takano, T | 1 |
| Nagasawa, J | 1 |
| Ohashi, T | 1 |
| Sakata, J | 1 |
| Haraguchi, Y | 1 |
| Eto, T | 1 |
| Ogoshi, K | 1 |
| Kato, T | 2 |
| Sakagawa, T | 1 |
| Ponce, J | 1 |
| Nos, P | 1 |
| Lamouliatte, H | 3 |
| Kohli, Y | 1 |
| Azuma, T | 1 |
| Ito, S | 1 |
| Hirai, M | 1 |
| Michel, P | 1 |
| Duhamel, C | 1 |
| Bazin, B | 1 |
| Raoul, JL | 1 |
| Person, B | 1 |
| Bigard, MA | 1 |
| Legoux, JL | 1 |
| Sallerin, V | 2 |
| Colin, R | 1 |
| Ekström, P | 1 |
| Carling, L | 1 |
| Unge, P | 1 |
| Anker-Hansen, O | 1 |
| Sjöstedt, S | 1 |
| Sellström, H | 1 |
| Florent, C | 1 |
| Lanza, F | 3 |
| Goff, J | 2 |
| Scowcroft, C | 1 |
| Jennings, D | 2 |
| Greski-Rose, P | 2 |
| Seifert, E | 1 |
| Pallone, F | 2 |
| Luzza, F | 2 |
| Delle Fave, G | 1 |
| Annibale, B | 1 |
| Marcheggiano, A | 1 |
| Biancone, L | 1 |
| Torsoli, A | 1 |
| Capurso, L | 1 |
| Hawkey, CJ | 1 |
| Long, RG | 1 |
| Bardhan, KD | 4 |
| Wormsley, KG | 1 |
| Cochran, KM | 1 |
| Christian, J | 1 |
| Moules, IK | 1 |
| Petite, JP | 1 |
| Slama, JL | 1 |
| Licht, H | 1 |
| Lemerez, M | 1 |
| Coste, T | 1 |
| Andrieu, J | 1 |
| Grimaud, JC | 1 |
| Julien, H | 1 |
| Dupuis, J | 1 |
| Mignon, M | 2 |
| Vallot, T | 1 |
| Brunner, G | 1 |
| Arnold, R | 1 |
| Hennig, U | 2 |
| Fuchs, W | 1 |
| Cadiot, G | 1 |
| Vissuzaine, C | 1 |
| Pospai, D | 1 |
| Ruszniewski, P | 1 |
| Potet, F | 1 |
| Avner, DL | 1 |
| Dorsch, ER | 1 |
| Jennings, DE | 2 |
| Greski-Rose, PA | 1 |
| Poynard, T | 1 |
| Lemaire, M | 1 |
| Agostini, H | 1 |
| Schütze, K | 1 |
| Hentschel, E | 1 |
| Pei, Y | 1 |
| Wang, B | 1 |
| Chen, S | 1 |
| Parente, F | 1 |
| Maconi, G | 2 |
| Bargiggia, S | 2 |
| Colombo, E | 1 |
| Bianchi Porro, G | 3 |
| Stermer, E | 1 |
| Levy, N | 1 |
| Sito, E | 1 |
| Konturek, PC | 1 |
| Bielański, W | 1 |
| Kwiecień, N | 1 |
| Konturek, SJ | 1 |
| Baniukiewicz, A | 1 |
| Jedynak, M | 1 |
| Gabryelewicz, A | 1 |
| Hahn, EG | 1 |
| de Boer, WA | 1 |
| van Etten, RJ | 1 |
| Schade, RW | 1 |
| Ouwehand, ME | 1 |
| Schneeberger, PM | 1 |
| Tytgat, GN | 2 |
| Shaw, S | 1 |
| Dhar, A | 2 |
| Gupta, VK | 1 |
| Srinivasan, S | 1 |
| Logan, RP | 1 |
| Kato, M | 1 |
| Kudo, M | 1 |
| Sukegawa, M | 1 |
| Koshiyama, T | 1 |
| Nishikawa, K | 1 |
| Hokari, K | 1 |
| Maruyama, M | 1 |
| Murakami, M | 1 |
| Saita, H | 2 |
| Tsuji, S | 1 |
| Gisbert, JP | 2 |
| Boixeda, D | 2 |
| Alvarez Baleriola, I | 1 |
| Martín de Argila, C | 2 |
| Bermejo, F | 1 |
| Aller, R | 1 |
| Baba, S | 2 |
| Caselli, M | 1 |
| Trevisani, L | 1 |
| Tursi, A | 1 |
| Sartori, S | 1 |
| Ruina, M | 1 |
| Luzzi, I | 1 |
| Gaudenzi, P | 1 |
| Alvisi, V | 1 |
| Gasbarrini, G | 1 |
| Lazzaroni, M | 1 |
| Seki, H | 1 |
| Nakao, K | 1 |
| Imoto, I | 1 |
| Ikemura, N | 1 |
| Shibata, T | 1 |
| Takaji, S | 1 |
| Taguchi, Y | 1 |
| Misaki, M | 1 |
| Yamauchi, K | 1 |
| Yamazaki, N | 1 |
| Kayser, S | 1 |
| Flury, R | 1 |
| Zbinden, R | 1 |
| Fried, M | 1 |
| Wirth, HP | 1 |
| Leufkens, H | 1 |
| Claessens, A | 1 |
| Heerdink, E | 1 |
| van Eijk, J | 1 |
| Lamers, CB | 1 |
| Harford, W | 1 |
| Arora, A | 1 |
| Graham, D | 1 |
| Haber, M | 3 |
| Weissfeld, A | 2 |
| Rose, P | 3 |
| Siepman, N | 2 |
| Jaup, BK | 1 |
| Silvers, D | 1 |
| Winters, J | 1 |
| Jhala, N | 1 |
| Misiewicz, JJ | 2 |
| Harris, AW | 2 |
| Levi, S | 2 |
| O'Morain, C | 2 |
| Cooper, BT | 2 |
| Kerr, GD | 2 |
| Dixon, MF | 2 |
| Langworthy, H | 2 |
| Piper, D | 2 |
| Russo, A | 2 |
| Dattilo, M | 1 |
| Suzuki, M | 3 |
| Mori, M | 2 |
| Miyayama, A | 1 |
| Iwai, N | 1 |
| Tsunematsu, N | 1 |
| Oonuki, M | 1 |
| Schwartz, H | 1 |
| Krause, R | 1 |
| Sahba, B | 1 |
| Freston, J | 1 |
| Mehdi, A | 1 |
| Ajmi, S | 1 |
| Liu, W | 1 |
| Lü, B | 1 |
| Xiao, S | 1 |
| Takashima, M | 3 |
| Kajimura, M | 1 |
| Treiber, G | 1 |
| Lambert, JR | 1 |
| Bal, C | 1 |
| Meining, A | 1 |
| Kiel, G | 1 |
| Stolte, M | 1 |
| Cayla, R | 1 |
| Zerbib, F | 1 |
| Forestier, S | 1 |
| de Mascarel, A | 1 |
| Joubert-Collin, M | 2 |
| Mégraud, F | 1 |
| Ritsuno, H | 1 |
| Ohnuma, K | 1 |
| Suzuki, J | 1 |
| Kobayasi, I | 1 |
| Fujita, T | 1 |
| Kitahora, T | 2 |
| Nagahashi, S | 2 |
| Zhang, T | 1 |
| O'Keefe, SJ | 1 |
| Winter, T | 1 |
| Marks, IN | 1 |
| Ogden, J | 1 |
| Liu, WZ | 1 |
| Xiao, SD | 2 |
| Shi, Y | 1 |
| Wu, SM | 1 |
| Zhang, DZ | 1 |
| Xu, WW | 1 |
| Takeuchi, K | 1 |
| Konaka, A | 1 |
| Nishijima, M | 1 |
| Yasuhiro, T | 1 |
| Cammarota, G | 1 |
| Papa, A | 1 |
| Cianci, R | 1 |
| Cannizzaro, O | 1 |
| Armuzzi, A | 1 |
| Gasbarrini, A | 1 |
| Addolorato, G | 1 |
| Gasbarrini, GB | 1 |
| Crowe, J | 1 |
| Thompson, RP | 1 |
| Trewby, PN | 1 |
| Keeling, PN | 1 |
| Weir, D | 1 |
| Crouch, SL | 1 |
| Kovacs, TO | 1 |
| Campbell, D | 1 |
| Richter, J | 1 |
| Kromer, W | 1 |
| Horbach, S | 1 |
| Lühmann, R | 1 |
| Dobrilla, G | 1 |
| Piazzi, L | 1 |
| Fiocca, R | 2 |
| Tennvall, GR | 1 |
| Norinder, A | 1 |
| Ohlin, B | 1 |
| Sou, Y | 1 |
| Takahashi, Y | 1 |
| Yoshinaga, T | 1 |
| Matsukawa, Y | 1 |
| Sekikawa, A | 1 |
| Nakazawa, T | 1 |
| Shio, S | 1 |
| Kohigashi, K | 1 |
| Bustamante, M | 1 |
| Stollman, N | 1 |
| Wong, BC | 2 |
| Hu, FL | 2 |
| Qian, SC | 1 |
| Huang, NX | 1 |
| Li, YY | 1 |
| Hu, PJ | 1 |
| Manan, C | 1 |
| Lesmana, L | 1 |
| Carpio, RE | 1 |
| Perez, JY | 1 |
| Fock, KM | 1 |
| Kachintorn, U | 1 |
| Phornphutkul, K | 1 |
| Kullavanijaya, P | 1 |
| Ho, J | 1 |
| Lam, SK | 2 |
| Gomollón, F | 1 |
| Santolaria, S | 1 |
| Ducóns, JA | 1 |
| Guirao, R | 1 |
| Vera, J | 1 |
| Montoro, M | 1 |
| Shashidhar, H | 1 |
| Peters, J | 1 |
| Lin, CH | 1 |
| Rabah, R | 1 |
| Thomas, R | 1 |
| Tolia, V | 1 |
| Perie, F | 1 |
| Di Mario, F | 1 |
| Battaglia, F | 1 |
| Dal Bò, N | 1 |
| Leandro, G | 1 |
| Benedetti, E | 1 |
| Bottona, E | 1 |
| Caroli, A | 1 |
| Costan-Biedo, F | 1 |
| De Bastiani, R | 1 |
| Germanà, B | 1 |
| Andrea Grassi, S | 1 |
| Madia, D | 1 |
| Marcon, V | 1 |
| Marin, R | 1 |
| Monica, F | 1 |
| Olivieri, P | 1 |
| Orzes, N | 1 |
| Pilotto, A | 1 |
| Ronzani, G | 1 |
| Saggioro, A | 1 |
| Tafner, G | 1 |
| Buzás György, M | 1 |
| Székely, E | 1 |
| Illyés, G | 1 |
| Széles, I | 1 |
| Thomson, AB | 1 |
| Hoshihara, Y | 1 |
| Nakamura, T | 1 |
| Kajiyama, G | 1 |
| Ogawa, N | 2 |
| Yao, T | 1 |
| Muto, Y | 1 |
| Nakazawa, S | 1 |
| Takemoto, T | 1 |
| Fanti, L | 1 |
| Ieri, R | 1 |
| Mezzi, G | 1 |
| Testoni, PA | 1 |
| Passaretti, S | 1 |
| Guslandi, M | 1 |
| Shirai, N | 1 |
| Xiao, F | 1 |
| Sugimura, H | 1 |
| Ohashi, K | 1 |
| Ishizaki, T | 1 |
| Wang, WH | 1 |
| Wong, WM | 1 |
| Lau, GK | 1 |
| Fung, FM | 1 |
| Kung, NN | 1 |
| Chu, KM | 1 |
| Lai, KC | 1 |
| Hu, WH | 1 |
| Liu, XG | 1 |
| Chan, CK | 1 |
| Yuen, MF | 1 |
| Hui, WM | 1 |
| Bardou, M | 1 |
| Giglio, A | 1 |
| Ciliberto, E | 1 |
| Belmonte, A | 1 |
| Cavaliere, C | 1 |
| Saccà, N | 1 |
| Frandina, C | 1 |
| Trimboli, V | 1 |
| Meyer, JM | 1 |
| Silliman, NP | 1 |
| Dixon, CA | 1 |
| Siepman, NY | 1 |
| Sugg, JE | 1 |
| Hopkins, RJ | 1 |
| Bateson, MC | 1 |
| Imbesi, V | 1 |
| Cucino, C | 1 |
| Yang, JC | 1 |
| Yang, KC | 1 |
| Hsu, CT | 1 |
| Wang, CS | 1 |
| Kuo, CF | 1 |
| Herszényi, L | 1 |
| Tulassay, Z | 1 |
| Ikeda, S | 1 |
| Tamamuro, T | 1 |
| Hamashima, C | 1 |
| Mai, AL | 1 |
| Mai, KT | 1 |
| Miyazawa, M | 1 |
| Suzuki, K | 1 |
| Bown, RL | 1 |
| Barradell, LB | 1 |
| Faulds, D | 1 |
| McTavish, D | 1 |
| Berlin, I | 1 |
| Molinier, P | 1 |
| Duchier, A | 1 |
| Cournot, A | 1 |
| Durrel, J | 1 |
| Dellatolas, F | 1 |
| Duchier, J | 1 |
| Hotz, J | 1 |
| Kleinert, R | 2 |
| Grymbowski, T | 1 |
| Schwarz, JA | 1 |
| Inatomi, N | 1 |
| Nagaya, H | 1 |
| Takami, K | 1 |
| Shino, A | 1 |
| Londong, W | 1 |
| Barth, H | 1 |
| Dammann, HG | 1 |
| Hengels, KJ | 1 |
| Müller, P | 1 |
| Rohde, H | 1 |
| Simon, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Recurrent Idiopathic Gastroduodenal Ulcer Bleeding: a Double-blind Randomized Trial[NCT01180179] | Phase 4 | 228 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Efficacy of Vonoprazan Versus Intravenous Proton Pump Inhibitors for Prevention of Rebleeding in High Risk Peptic Ulcers Bleeding After Successful Endoscopic Hemostasis[NCT05005910] | Early Phase 1 | 194 participants (Actual) | Interventional | 2021-09-01 | Completed | ||
| A Phase 3, Randomized, Double Blind, Double-Dummy, Multicenter, Parallel Group Comparison Study to on Efficacy and Safety of Oral Once-Daily Administration of TAK-438 20 mg Comparing With AG-1749 in Patients With Duodenal Ulcer[NCT01452724] | Phase 3 | 372 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Phase 3, Randomized, Double Blind, Double-Dummy, Multicenter, Parallel Group Comparison Study to on Efficacy and Safety of Oral Once-Daily Administration of TAK-438 20 mg Comparing With AG-1749 in Patients With Gastric Ulcer.[NCT01452711] | Phase 3 | 482 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| The Phase 2 Study of FP-10, the Food Ingredient Derived From Milk Casein, on the Eradication Rates of Helicobacter Pylori by a Triple Therapy With Lansoprazole, Amoxicillin, and Clarithromycin[NCT00281047] | Phase 2/Phase 3 | 138 participants | Interventional | 2006-01-31 | Recruiting | ||
| Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors[NCT00204373] | Phase 4 | 72 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| European Registry on the Management of Helicobacter Pylori Infection[NCT02328131] | 10,000 participants (Anticipated) | Observational | 2013-06-30 | Recruiting | |||
| A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of Lansoprazole 30 mg QD and Naproxen 500 mg BID Versus Celecoxib 200 mg QD in Risk Reduction of Non Steroidal Anti-Inflammatory-Associated Ulcers in Osteoarthritis Subjects Taki[NCT00175032] | Phase 3 | 1,045 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| Pharmacodynamic Dose-Response of S-Tenatoprazole-Na (STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers[NCT00284908] | Phase 1 | 32 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Assessment of the Healing Rate of Erosive or Ulcerative Esophagitis After Two and Four Weeks of Treatment With S-Tenatoprazole-Na (STU-Na) 15 mg, 30 mg, 60 mg, 90 mg and Esomeprazole 40 mg. A Multicenter, Randomized, Double-Blind, Parallel Group Study.[NCT00282555] | Phase 2 | 450 participants | Interventional | 2006-02-28 | Suspended | ||
| Pharmacogenomics-Based Tailor-Made Strategy for Eradication of Helicobacter Pylori[NCT00149084] | Phase 3 | 296 participants | Interventional | 2003-04-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
number of participants with control of gastric acid production (NCT00204373)
Timeframe: up to 240 months from study enrollment
| Intervention | participants (Number) |
|---|---|
| Single Group | 72 |
The median survival from the time of diagnosis (NCT00204373)
Timeframe: survival or up to 240 months
| Intervention | years (Median) |
|---|---|
| Single Group | 6.6 |
19 reviews available for lansoprazole and Duodenal Ulcer
| Article | Year |
|---|---|
Upper gastrointestinal bleed associated with cholinesterase inhibitor use.
Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Duodenal Ulcer; Endoscop | 2015 |
[Proton pump inhibitors, a family of drugs in continuous expansion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Barrett E | 2000 |
Discovery of lansoprazole and its unique pharmacological properties independent from anti-secretory activity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Duodenal | 2013 |
Helicobacter heilmannii infection in a child after successful eradication of Helicobacter pylori: case report and review of literature.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chil | 2005 |
[Lansoprazol].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Controlled Clinical Trials as Topic; Duo | 1995 |
Adjuvant therapy for Helicobacter pylori eradication: role of lansoprazole in clinical studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Chemotherapy, Adj | 1995 |
Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Gastritis; Gastroesophag | 1993 |
[Lansoprazole--profile of a new proton pump inhibitor].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug A | 1994 |
Acute treatment of duodenal ulcer: experience with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Administration Schedule; Duodenal U | 1993 |
Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Anti-Ulcer Agents; Duodenal Ulcer; Famotidin | 1995 |
The impact of Helicobacter pylori eradication on peptic ulcer healing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer | 1998 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
The efficacy of proton-pump inhibitors in acute ulcer bleeding: a qualitative review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Humans; | 2000 |
Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Duode | 2000 |
[H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Ulcer Agents; Benzimidazoles; Child | 2001 |
Helicobacter pylori and early duodenal ulcer status post-treatment: a review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clinical | 2001 |
[Comparative study of proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 2001 |
An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Digestive System Diseases; Duodenal Ulcer; Dyspepsia; Enzym | 2002 |
Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biological Availability; Duodenal Ulcer; | 1992 |
91 trials available for lansoprazole and Duodenal Ulcer
| Article | Year |
|---|---|
Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients.
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duod | 2022 |
Efficacy of keverprazan for duodenal ulcer: A phase II randomized, double-blind, parallel-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Fol | 2022 |
Efficacy and Safety of Keverprazan Compared With Lansoprazole in the Treatment of Duodenal Ulcer: A Phase III, Randomized, Double-Blind, Multicenter Trial.
Topics: Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Humans; Lansoprazole | 2023 |
Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; Histamine H2 Antag | 2020 |
Endoscopic evaluation of low-dose aspirin-induced gastric and duodenal ulcers during prophylaxis with lansoprazole.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Comorbidity; Double-Blind | 2013 |
Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Endoscopy; Female; Humans; Lans | 2017 |
Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Endoscopy; Female; Humans; Lans | 2017 |
Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Endoscopy; Female; Humans; Lans | 2017 |
Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Endoscopy; Female; Humans; Lans | 2017 |
Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Endoscopy; Female; Humans; Lans | 2017 |
Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Endoscopy; Female; Humans; Lans | 2017 |
Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Endoscopy; Female; Humans; Lans | 2017 |
Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Endoscopy; Female; Humans; Lans | 2017 |
Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Endoscopy; Female; Humans; Lans | 2017 |
Does pretreatment with lansoprazole influence Helicobacter pylori eradication rate and quality of life?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Amoxicillin; Clarithromycin; D | 2010 |
Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Aspirin; Double-Blind Method; Duod | 2011 |
Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A | 2012 |
Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2002 |
Density of Helicobacter pylori may affect the efficacy of eradication therapy and ulcer healing in patients with active duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2003 |
Rank order of success favors longer duration of imidazole-based therapy for Helicobacter pylori in duodenal ulcer disease: a randomized pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2004 |
In treatment of active duodenal ulcer and Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2003 |
Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, N | 2004 |
Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Esophagitis | 2005 |
Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agent | 2005 |
Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2007 |
The effects of short-term lansoprazole therapy on Helicobacter pylori infection and antral gastritis in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 1995 |
Lansoprazole versus lansoprazole plus amoxicillin treatment for eradication of Helicobacter pylori in patients with gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; | 1995 |
Clinical efficacy of lansoprazole in eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Drug Administration | 1995 |
Effects of lansoprazole with or without amoxicillin on ulcer healing: relation to eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Duodenal Ulcer; Gastric Jui | 1995 |
Efficacy of lansoprazole in eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz | 1995 |
Efficacy of lansoprazole and amoxicillin in eradicating Helicobacter pylori: evaluation using 13C-UBT and Monoclonal H. pylori antibody testing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Antibodies, Bacterial; Anti | 1995 |
Eradication of Helicobacter pylori with lansoprazole, amoxicillin, and plaunotol in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Diterpenes; Dr | 1995 |
Quality of peptic ulcer healing induced by lansoprazole and roxatidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Duodenal | 1995 |
Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Atrophy; Duodenal Ulcer; Gastric Mucosa; | 1995 |
Lansoprazole for maintenance therapy of peptic ulcer disease: weekend full-dose or everyday half-dose administration?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Drug Administration Schedule; Duo | 1995 |
The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Antibodi | 1995 |
Effect of lansoprazole on peptic ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Female; Helicobacter Inf | 1995 |
Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Helicobacter Infections; | 1995 |
Lansoprazole treatment of Helicobacter pylori-positive peptic ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulce | 1995 |
[Lansoprazole versus ranitidine in the prevention of early recurrences of digestive hemorrhages from gastroduodenal ulcers. Randomized double-blind multicenter study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 1994 |
Lansoprazole versus omeprazole in active duodenal ulcer. A double-blind, randomized, comparative study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Double-Blind Method; Duodenal Ulcer; Female; Humans; Lansop | 1995 |
Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Lansoprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adult; Anti-Ulcer Agents; Double-Blind Metho | 1994 |
Lansoprazole and Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Double-Blind Method; | 1993 |
Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Me | 1993 |
[Comparison of lansoprazole (30 mg) and omeprazole (20 mg) in the treatment of duodenal ulcer. A multicenter double-blind comparative trial].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Double-Blin | 1993 |
Acute treatment of duodenal ulcer: experience with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Administration Schedule; Duodenal U | 1993 |
An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug A | 1993 |
A comparison of three doses of lansoprazole (15, 30 and 60 mg) and placebo in the treatment of duodenal ulcer. The Lansoprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Aged; Anti-Ulcer Agents; Double-Blin | 1995 |
[A clinical trial of lansoprazole in the treatment of duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Female; H(+ | 1995 |
Comparison of two lansoprazole-antibiotic combinations (amoxycillin or classical triple therapy) for treatment of H. pylori infection in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Antitrichomonal Agents; Dru | 1996 |
One week treatment with omeprazole, clarithromycin and tinidazole or lansoprazole, amoxicillin and metronidazole for cure of Helicobacter pylori infection in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 1996 |
4-day lansoprazole quadruple therapy: a highly effective cure for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; | 1996 |
Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Enzyme Inhibitors | 1996 |
Effects of lansoprazole plus amoxycillin on the cure of Helicobacter pylori infection in Japanese peptic ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Amoxicillin; Anti-Ulcer | 1996 |
[Effect of treatment with lansoprazole and amoxicillin in combination on healing process of duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Drug Therapy, Combination; Duoden | 1996 |
Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Bacterial Agents; A | 1997 |
Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1997 |
[Comparative effect of lansoprazole/amoxicillin with omeprazole/amoxicillin for the eradication of Helicobacter pylori in patients with duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Age | 1997 |
Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Diar | 1996 |
Prevention of duodenal ulcer recurrence with 15 mg lansoprazole: a double-blind placebo-controlled study. The Lansoprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Biopsy; Double-Blind Method | 1997 |
One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Age | 1997 |
Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Bed Rest; Dose- | 1997 |
Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
[Effect of the observance of diurnal fast of Ramadan on duodenal ulcer healing with lansoprazole. Results of a prospective controlled study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Fasting; Female; | 1997 |
[Clarithromycin combined short-term triple therapies for eradication of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithrom | 1996 |
Amount of Helicobacter pylori in gastric mucus during anti-H. pylori treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combin | 1998 |
Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Female; Gas | 1998 |
Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Dual therapy using a double dose of lansoprazole with amoxicillin versus triple therapy using a double dose of lansoprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori infection: results of a prospective randomized open study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin | 1998 |
Safety and efficacy of one-week triple therapy for eradicating Helicobacter pylori in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Can the C-14 urea breath test replace follow-up endoscopic biopsies in patients treated for Helicobacter pylori infection?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Br | 1998 |
Effect of chronic duodenal ulceration and its treatment with lanzoprazole or sucralfate on gastroduodenal mucosal protein turnover and TGF-alpha, bFGF, and EGF receptor expression in humans.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Chronic Disease; Duodenal Ulcer; | 1998 |
[Previous treatment with omeprazole and H. pylori: does it diminish the eradication efficacy of the "new" triple therapies of one week's duration?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 1998 |
Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Infective Agents, Local; | 1999 |
Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 1999 |
Lansoprazole is superior to ranitidine as maintenance treatment for the prevention of duodenal ulcer relapse.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Me | 1999 |
Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2-receptor antagonists.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Drug R | 1999 |
Lansoprazole versus omeprazole for duodenal ulcer healing and prevention of relapse: a randomized, multicenter, double-masked trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Me | 1999 |
Cost effectiveness of Helicobacter pylori eradication therapies in patients with duodenal ulcer. An analysis of triple therapy versus two dual therapy alternatives.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Age | 1999 |
Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2000 |
A prospective trial of lansoprazole triple therapy for pediatric Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Biop | 2000 |
[Treatment of Helicobacter pylori infection with lansoprazole 30 mg or 60 mg combined with two antibiotics for duodenal ulcers].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2000 |
Cure of Helicobacter pylori-positive active duodenal ulcer patients: a double-blind, multicentre, 12-month study comparing a two-week dual vs a one-week triple therapy. GISU (Interdisciplinary Group for Ulcer Study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adult; Aged; Aged, 80 and over; Amoxicillin; | 2000 |
[Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; C | 2000 |
Peptic ulcer recurrence during maintenance therapy with H2-receptor antagonist following first-line therapy with proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Female; Histamine | 2000 |
Long-term follow-up and serologic assessment after triple therapy with omeprazole or lansoprazole of Helicobacter-associated duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies | 2001 |
Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl | 2001 |
Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Antacids; An | 2001 |
Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Bismuth; Clarit | 2001 |
Quadruple therapy for symptomatic spontaneous duodenal ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clarithr | 2001 |
Prolonging proton pump inhibitor-based anti-Helicobacter pylori treatment from one to two weeks in duodenal ulcer: is it worthwhile?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Amoxicillin; Anti-Bacterial Ag | 2000 |
A multicenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom | 1999 |
Treatment with a proton pump inhibitor promotes corpus gastritis in patients with Helicobacter pylori-infected antrum-predominant gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Benzimidazoles; Biopsy; | 2002 |
[Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adolescent; Adult; Aged; Anti-Ul | 1992 |
Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biological Availability; Duodenal Ulcer; | 1992 |
Dose ranging study of lansoprazole, a new proton pump inhibitor, in patients with high gastric acid secretion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Double-Blind Method; Drug | 1992 |
Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duoden | 1992 |
Dose-related healing of duodenal ulcer with the proton pump inhibitor lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Dose-Response R | 1991 |
42 other studies available for lansoprazole and Duodenal Ulcer
| Article | Year |
|---|---|
[THE FEATURES OF SECRETION AND STOMACH MOTOR PROCESSES IN PATIENTS WITH DUODENAL ULCERS AS A CAUSE FOR REDUCING BIOAVAILABILITY OF PROTON PUMP INHIBITORS].
Topics: Adolescent; Adult; Aged; Duodenal Ulcer; Female; Gastric Mucosa; Humans; Hydrogen-Ion Concentration; | 2015 |
Normalization of phospholipids concentration of the gastric mucosa was observed in patients with peptic ulcer after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2002 |
One week regimen of esomeprazole based triple therapy is sufficient for duodenal ulcer healing and Helicobacter pylori eradication in patients with duodenal ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Administration Schedule; | 2002 |
[Results of pre- and postoperative treatment of complicated duodenal ulcers with proton pump inhibitors ].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulce | 2002 |
Long-term follow-up of gastric metaplasia after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Cicatrix; Convalescence; Drug The | 2003 |
[Is gastric and duodenal ulcer drug-treatable or surgical disease?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Humans; Lansoprazole; Om | 1997 |
Gastric myoelectrical activity in patients with recurrent gastric or duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Endoscopy, Digest | 2003 |
Low dose, one-week triple therapy (lanzoprazole, amoxycillin, clarithromycin) for eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Drug Therapy, Com | 2003 |
[Chronic upper abdominal pain without improvement after using proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Anti-Ulcer Agents; Azathioprine; Duodenal U | 2004 |
Enhanced ghrelin secretion in rats with cysteamine-induced duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Cysteamine; Duodenal Ulcer; Gas | 2005 |
[Distribution of Helicobacter pylori in stomach before and after the administration of Lansoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Gastric Mucosa; Gastriti | 2005 |
Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adult; Amoxicillin; Anti-Bacterial Agents; A | 2005 |
Cholecystoduodenal fistula secondary to penetrating duodenal ulcer: a case of conservative management.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Duodenal Ul | 2006 |
Subacute cutaneous lupus erythematosus induced or exacerbated by proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Autoantibodies; Duodenal Ulcer; Esophagitis; Female; Humans | 2008 |
Lansoprazole--a new proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; | 1995 |
Second proton-pump inhibitor marketed.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Esophagitis; Humans; Lan | 1995 |
Clinical study on the pathophysiology and treatment of PPI-resistant ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Resistance; Duodenal Ulcer; Gastric | 1995 |
Factors affecting quality of ulcer healing after lansoprazole treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Alcohol Drinking; Anti-Ulcer Agents; Duodenal | 1995 |
Lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Controlled Clinical Trials as Topic; Cos | 1995 |
[Effect of prolonged treatment with proton pump inhibitors on serum gastrin levels and the fundus mucosa. Preliminary results].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Duodenal Ulcer; Enzyme Inhi | 1995 |
Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1995 |
Helicobacter pylori and lanzoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Gastritis; Helicobacter | 1996 |
Re: short-term treatment with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Helicobacter Infections; | 1996 |
The chemotherapeutic effects of H+/K+ inhibitors on Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Down-Regulation; Duodenal Ulcer; Enzyme Inhibitors; Helicob | 1996 |
Effect of lansoprazole in mono-, dual-, or triple therapy on Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; | 1996 |
[Erradicating treatment of Helicobacter pylori with lansoprazole and amoxicillin in duodenal ulcer patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug | 1996 |
Percentage changes in serum pepsinogens are useful as indices of eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Duodenal Ulcer; | 1997 |
Gastric metaplasia and Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer | 1997 |
Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ammonia; Anti-Bacterial Agents; Anti-Ulcer Agents; Biomarke | 1997 |
A prospective follow-up study of 5669 users of lansoprazole in daily practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 1997 |
Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin, and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Clinical Tr | 1996 |
Enhancement of neutrophil infiltration in the corpus after failure of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biop | 1997 |
Effect of Helicobacter pylori infection on gastric juice pH.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ammonia; Amoxicillin; Anti-Ulcer Agents; Case-Control Studi | 1998 |
Relationship between the eradication of Helicobacter pylori and the healing pattern of peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Gastric urease activity is inversely associated with the success of treatment for Helicobacter pylori: effect of sofalcone.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Breath Tests; | 1998 |
Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetic Acid; Animals; Anti-Ulcer Agents; Benzimidazoles; Bi | 1999 |
Relapse of duodenal ulcers after successful eradication of Helicobacter pylori in gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 1999 |
[Does eliminating Helicobacter pylori mean the healing of the duodenal ulcer? The results of a prospective study in Spain].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2000 |
Evaluation of the cost-effectiveness of Helicobacter pylori eradication triple therapy vs. conventional therapy for ulcers in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2001 |
Fine-needle aspiration biopsy of an intra-abdominal inflammatory mass secondary to a penetrating duodenal ulcer mimicking neoplasm.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Biopsy, Needle; Clarithromycin; Diagnosis, Dif | 2001 |
Effects of a proton pump inhibitor, AG-1749 (lansoprazole), on reflux esophagitis and experimental ulcers in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Duodenal Ulcer; Duodenum; Esoph | 1991 |
[AG1749: a study of its inhibition of gastric pH after morning or evening dosage].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Depression, Chemical; Drug Administration Schedule; | 1988 |